Drug reference

Brigatinib

Tyrosine Kinase Inhibitor · Antineoplastic

Tyrosine Kinase InhibitorAntineoplastic

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

FDA category + note

Top interactionssee all 12 →

AdalimumabSevereDatabaseDDInter
AmprenavirSevereDatabaseDDInter
ApalutamideSevereDatabaseDDInter
AprepitantSevereDatabaseDDInter

Mechanism

Brigatinib is a tyrosine kinase inhibitor. It targets and inhibits anaplastic lymphoma kinase (ALK), which is implicated in ALK-positive non-small cell lung cancer.

Indications

Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer previously treated with crizotinib (specialist use only)ALK-positive metastatic NSCLCfirst-line treatment for ALK-positive metastatic NSCLC

Dosing

Adult: Initially 90 mg once daily for 7 days, then increased to 180 mg once daily. If concomitant use with potent CYP3A4 inhibitors is unavoidable, reduce brigatinib dose to 90 mg once daily.
Renal adjustment: Reduced dosing is recommended with hepatic or renal impairment.
Hepatic adjustment: Reduced dosing is recommended with hepatic or renal impairment.

Pharmacokinetics

Half-life

25 h

Metabolism

CYP3A

Excretion

through the urine

Side effects

Common

Anaemiaappetite decreasedarrhythmiasarthralgiaastheniacataractchest discomfortconstipationcoughdiarrhoeadizzinessdry mouthdyspnoeaelectrolyte imbalanceeye disorderseye inflammationfacial swellingfeverflatulencegastrointestinal discomfortglaucomaheadacheshyperbilirubinaemiahyperglycaemiahyperinsulinaemiahypertensionincreased risk of infectioninsomniamemory lossmuscle complaintsmusculoskeletal discomfortnauseanerve disordersneurotoxicityoedemaoral disorderspainpalpitationsperipheral swellingphot

Serious